STOCK TITAN

[Form 4] Camp4 Therapeutics Corp Insider Trading Activity

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
4

Andrew J. Schwab, a director and 10% owner of Camp4 Therapeutics Corp (CAMP), reported an acquisition on Form 4. The filing shows a transaction dated 09/11/2025 in which 2,941,176 shares of common stock were acquired at $1.53 per share. The shares are reported as indirectly owned through 5AM Ventures VII, L.P. The filing also discloses additional indirect holdings attributed to related 5AM entities: 2,625,145 shares held by 5AM Ventures VI, L.P. and 302,770 shares held by 5AM Opportunities II, L.P. Explanatory footnotes state Schwab is a managing member of the general partner entities and disclaims direct beneficial ownership except to the extent of pecuniary interest.

Andrew J. Schwab, amministratore e proprietario del 10% di Camp4 Therapeutics Corp (CAMP), ha riportato un'acquisizione tramite Modulo 4. La dichiarazione mostra una transazione datata 11/09/2025 in cui sono state acquisite 2.941.176 azioni ordinarie al prezzo di 1,53 USD per azione. Le azioni sono segnalate come possedute indirettamente tramite 5AM Ventures VII, L.P. La dichiarazione rende inoltre note ulteriori partecipazioni indirette attribuite a entità correlate di 5AM: 2.625.145 azioni detenute da 5AM Ventures VI, L.P. e 302.770 azioni detenute da 5AM Opportunities II, L.P. Note esplicative indicano che Schwab è membro gestore delle entità del socio general e rinuncia alla proprietà beneficiaria diretta salvo per la parte di interesse pecuniario.
Andrew J. Schwab, director y titular del 10% de Camp4 Therapeutics Corp (CAMP), reportó una adquisición en el Formulario 4. El archivo muestra una transacción con fecha 11/09/2025 en la que se adquirieron 2.941.176 acciones comunes a 1,53 USD por acción. Las acciones se reportan como poseídas indirectamente a través de 5AM Ventures VII, L.P. El archivo también revela participaciones indirectas adicionales atribuidas a entidades asociadas de 5AM: 2.625.145 acciones en poder de 5AM Ventures VI, L.P. y 302.770 acciones en poder de 5AM Opportunities II, L.P. Notas explicativas indican que Schwab es miembro gerente de las entidades del socio general y no reclama la propiedad beneficiaria directa, salvo por el interés pecuniario.
Andrew J. Schwab는 Camp4 Therapeutics Corp(CAMP)의 이사이자 지분 10% 보유자로, Form 4에 보고했다. 파일에는 2025년 9월 11일자로 기재된 거래에서 주당 1.53달러에 2,941,176주를 취득한 것으로 나타난다. 이 주식은 5AM Ventures VII, L.P.를 통해 간접적으로 보유된 것으로 보고된다. 또한 5AM 계열사와 관련된 추가 간접 보유도 공개되었다: 5AM Ventures VI, L.P.가 보유한 2,625,145주와 5AM Opportunities II, L.P.가 보유한 302,770주. 주석은 Schwab가 일반 파트너 엔티티의 관리 구성원이며 재정적 이해관계 범위에 한해 직접적 유익 소유권을 부인한다는 내용을 담고 있다.
Andrew J. Schwab, administrateur et propriétaire de 10 % de Camp4 Therapeutics Corp (CAMP), a déclaré une acquisition sur le formulaire 4. Le dépôt montre une transaction datée du 11/09/2025 au cours de laquelle 2 941 176 actions ordinaires ont été acquises à 1,53 USD par action. Les actions sont déclarées comme détenues indirectement par l’intermédiaire de 5AM Ventures VII, L.P. Le dépôt révèle également des participations indirectes additionnelles attribuées à des entités associées à 5AM : 2 625 145 actions détenues par 5AM Ventures VI, L.P. et 302 770 actions détenues par 5AM Opportunities II, L.P. Des notes explicatives indiquent que Schwab est membre gestionnaire des entités du partenaire général et renonce à la propriété bénéficiaire directe, sauf dans la mesure de son intérêt pécuniaire.
Andrew J. Schwab, Direktor und 10 %-Eigentümer von Camp4 Therapeutics Corp (CAMP), meldete einen Erwerb im Formular 4. Der Eintrag zeigt eine Transaktion mit dem Datum 11.09.2025, bei der 2.941.176 Stammaktien zu 1,53 USD pro Aktie erworben wurden. Die Aktien werden als indirekt über 5AM Ventures VII, L.P. gehalten gemeldet. Die Einreichung offenbart zudem weitere indirekte Beteiligungen, die 5AM-Einheiten zugeordnet sind: 2.625.145 Aktien im Besitz von 5AM Ventures VI, L.P. und 302.770 Aktien im Besitz von 5AM Opportunities II, L.P. Erläuternde Fußnoten besagen, dass Schwab als verwaltendes Mitglied der Generalpartner-Entitäten fungiert und direkte wirtschaftliche Eigentumsrechte nur in dem Umfang anerkennt, wie er ein finanzielles Interesse hat.
أندرو ج. شواب، مدير ومالك 10% من Camp4 Therapeutics Corp (CAMP)، أفاد بالاستحواذ في النموذج 4. يظهر الملف معاملة بتاريخ 11/09/2025 تم بموجبها شراء 2,941,176 سهماً من الأسهم العادية بسعر 1.53 دولار للسهم. تُذكر الأسهم كملك غير مباشر من خلال 5AM Ventures VII, L.P. كما يكشف الملف عن امتلاكيات غير مباشرة إضافية تُنسب إلى كيانات 5AM المرتبطة: 2,625,145 سهماً مملوكة لـ 5AM Ventures VI, L.P. و302,770 سهماً مملوكاً لـ 5AM Opportunities II, L.P. وتوضح الحواشي التفسيرية أن شواب هو عضو مدِير في كيانات الشريك العام ويتنصل من الملكية المفيدة المباشرة إلا بقدر مصالحه المالية.
Andrew J. Schwab, Camp4 Therapeutics Corp(CAMP)的董事兼10%所有者,已在 Form 4 上报告了一项收购。该 filing 显示日期为 2025 年 9 月 11 日的交易,购买了 2,941,176 股普通股,单价 1.53 美元。该等股票被报告为通过 5AM Ventures VII, L.P. 间接持有。申报还披露了归因于 5AM 相关实体的其他间接持有:5AM Ventures VI, L.P. 持有的 2,625,145 股,以及 5AM Opportunities II, L.P. 持有的 302,770 股。解释性脚注指出 Schwab 是普通合伙人实体的管理成员,除以其财政利益范围内的部分外,否认直接受益所有权。
Positive
  • None.
Negative
  • None.

Insights

TL;DR: Significant indirect acquisition reported: 2,941,176 shares purchased at $1.53, ownership held via 5AM Ventures VII.

The Form 4 documents a material non-derivative acquisition by entities associated with Andrew J. Schwab on 09/11/2025. The reported price of $1.53 per share for 2,941,176 shares is explicit and sizable for a single transaction. The filing clarifies the position is held indirectly through 5AM Ventures VII, with additional indirect stakes disclosed in affiliated 5AM vehicles. This indicates consolidated exposure from Schwab-affiliated funds rather than a personal, direct stake; the footnotes properly disclose the governance relationship and disclaimer of direct beneficial ownership.

TL;DR: Governance disclosure shows indirect holdings via venture fund structures with standard disclaimers of direct ownership.

The statement of changes in beneficial ownership follows Section 16 formatting and includes explanatory notes identifying the general partner entities and Schwab's role as a managing member. The filing appropriately reports indirect ownership through 5AM Ventures VII, VI and Opportunities II and includes the required signature and date. The disclosures are consistent with typical venture-fund-held insider reporting and clarify that Schwab disclaims direct beneficial ownership except for any pecuniary interest.

Andrew J. Schwab, amministratore e proprietario del 10% di Camp4 Therapeutics Corp (CAMP), ha riportato un'acquisizione tramite Modulo 4. La dichiarazione mostra una transazione datata 11/09/2025 in cui sono state acquisite 2.941.176 azioni ordinarie al prezzo di 1,53 USD per azione. Le azioni sono segnalate come possedute indirettamente tramite 5AM Ventures VII, L.P. La dichiarazione rende inoltre note ulteriori partecipazioni indirette attribuite a entità correlate di 5AM: 2.625.145 azioni detenute da 5AM Ventures VI, L.P. e 302.770 azioni detenute da 5AM Opportunities II, L.P. Note esplicative indicano che Schwab è membro gestore delle entità del socio general e rinuncia alla proprietà beneficiaria diretta salvo per la parte di interesse pecuniario.
Andrew J. Schwab, director y titular del 10% de Camp4 Therapeutics Corp (CAMP), reportó una adquisición en el Formulario 4. El archivo muestra una transacción con fecha 11/09/2025 en la que se adquirieron 2.941.176 acciones comunes a 1,53 USD por acción. Las acciones se reportan como poseídas indirectamente a través de 5AM Ventures VII, L.P. El archivo también revela participaciones indirectas adicionales atribuidas a entidades asociadas de 5AM: 2.625.145 acciones en poder de 5AM Ventures VI, L.P. y 302.770 acciones en poder de 5AM Opportunities II, L.P. Notas explicativas indican que Schwab es miembro gerente de las entidades del socio general y no reclama la propiedad beneficiaria directa, salvo por el interés pecuniario.
Andrew J. Schwab는 Camp4 Therapeutics Corp(CAMP)의 이사이자 지분 10% 보유자로, Form 4에 보고했다. 파일에는 2025년 9월 11일자로 기재된 거래에서 주당 1.53달러에 2,941,176주를 취득한 것으로 나타난다. 이 주식은 5AM Ventures VII, L.P.를 통해 간접적으로 보유된 것으로 보고된다. 또한 5AM 계열사와 관련된 추가 간접 보유도 공개되었다: 5AM Ventures VI, L.P.가 보유한 2,625,145주와 5AM Opportunities II, L.P.가 보유한 302,770주. 주석은 Schwab가 일반 파트너 엔티티의 관리 구성원이며 재정적 이해관계 범위에 한해 직접적 유익 소유권을 부인한다는 내용을 담고 있다.
Andrew J. Schwab, administrateur et propriétaire de 10 % de Camp4 Therapeutics Corp (CAMP), a déclaré une acquisition sur le formulaire 4. Le dépôt montre une transaction datée du 11/09/2025 au cours de laquelle 2 941 176 actions ordinaires ont été acquises à 1,53 USD par action. Les actions sont déclarées comme détenues indirectement par l’intermédiaire de 5AM Ventures VII, L.P. Le dépôt révèle également des participations indirectes additionnelles attribuées à des entités associées à 5AM : 2 625 145 actions détenues par 5AM Ventures VI, L.P. et 302 770 actions détenues par 5AM Opportunities II, L.P. Des notes explicatives indiquent que Schwab est membre gestionnaire des entités du partenaire général et renonce à la propriété bénéficiaire directe, sauf dans la mesure de son intérêt pécuniaire.
Andrew J. Schwab, Direktor und 10 %-Eigentümer von Camp4 Therapeutics Corp (CAMP), meldete einen Erwerb im Formular 4. Der Eintrag zeigt eine Transaktion mit dem Datum 11.09.2025, bei der 2.941.176 Stammaktien zu 1,53 USD pro Aktie erworben wurden. Die Aktien werden als indirekt über 5AM Ventures VII, L.P. gehalten gemeldet. Die Einreichung offenbart zudem weitere indirekte Beteiligungen, die 5AM-Einheiten zugeordnet sind: 2.625.145 Aktien im Besitz von 5AM Ventures VI, L.P. und 302.770 Aktien im Besitz von 5AM Opportunities II, L.P. Erläuternde Fußnoten besagen, dass Schwab als verwaltendes Mitglied der Generalpartner-Entitäten fungiert und direkte wirtschaftliche Eigentumsrechte nur in dem Umfang anerkennt, wie er ein finanzielles Interesse hat.
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
1. Name and Address of Reporting Person*
Schwab Andrew J.

(Last) (First) (Middle)
C/O 5AM VENTURE MANAGEMENT, LLC
4 EMBARCADERO CENTER, SUITE 3110

(Street)
SAN FRANCISCO CA 94111

(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director X 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
09/11/2025
4. If Amendment, Date of Original Filed (Month/Day/Year)
6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock 09/11/2025 A 2,941,176 A $1.53 2,941,176 I By 5AM Ventures VII, L.P.(1)
Common Stock 2,625,145 I By 5AM Ventures VI, L.P.(2)
Common Stock 302,770 I By 5AM Opportunities II, L.P.(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Explanation of Responses:
1. The shares are directly held by 5AM Ventures VII, L.P. ("Ventures VII"). 5AM Partners VII, LLC ("Partners VII") is the sole general partner of Ventures VII. The Reporting Person is a managing member of Partners VII and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VII. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
2. The shares are directly held by 5AM Ventures VI, L.P. ("Ventures VI"). 5AM Partners VI, LLC ("Partners VI") is the sole general partner of Ventures VI. The Reporting Person is a managing member of Partners VI and may be deemed to have shared voting and investment power over the shares beneficially owned by Ventures VI. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
3. The shares are directly held by 5AM Opportunities II, L.P. ("Opportunities II"). 5AM Opportunities II (GP), LLC ("Opportunities II GP") is the sole general partner of Opportunities II. The Reporting Person is a managing member of Opportunities II GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities II GP. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein.
/s/ Andrew J. Schwab 09/15/2025
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
Camp4 Therapeutics Corp.

NASDAQ:CAMP

CAMP Rankings

CAMP Latest News

CAMP Latest SEC Filings

CAMP Stock Data

60.48M
10.47M
35.19%
51.76%
1.08%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE